Category: <span>ipilimumab</span>

Category: ipilimumab

anti-CTLA-4, AstraZeneca, FDA, ipilimumab, Malignant mesothelioma, mesothelioma, Mesothelioma News, Orphan Drug, Orphan Drug Act of January 1983, Robert Iannone, tremelimumab

FDA Grants AstraZeneca’s Tremelimumab Orphan Drug Status for Mesothelioma

 

AstraZeneca’s tremelimumab (anti-CTLA-4 monoclonal antibody) has received Orphan Drug status from the FDA for treating malignant mesothelioma.